Open Access<p>CD26 as a Promising Biomarker for Predicting Prognosis in Patients with Pancreatic Tumors</p>
Author(s) -
Yan Liang,
Xiuyun Tian,
Chunxiang Ye,
Xiaoya Guan,
Bin Dong,
Min Zhao,
Jianhui Wu,
Chunyi Hao
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s278736
Subject(s) - pancreatic cancer , medicine , immunohistochemistry , malignancy , pathological , hazard ratio , pancreatic ductal adenocarcinoma , adenocarcinoma , oncology , pathology , cancer research , cancer , confidence interval
Pancreatic cancer is associated with a high mortality rate owing to insufficient approaches for early diagnosis and the invasive biological behavior of the cancer. CD26 is a membrane-anchored protein involved in multiple physiological and pathological processes. Here, we investigated correlations between CD26 expression and clinicopathological features in patients with pancreatic tumors.